Trisalus Life Sciences, Inc. income statement

In fiscal 2025, Trisalus Life Sciences, Inc. reported revenue of $45.2m, up 53.4% on the year before, operating income of −$26.9m (a -59.7% margin) and net income of −$39.2m, or −$1.84 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Trisalus Life Sciences, Inc.: income statement, annual
Fiscal year	2022Dec 2022	2023Dec 2023	2024Dec 2024	2025Dec 2025	LTMJun 2026
Revenue	12	19	29	45	45
Cost of revenue	2	3	4	7	6
Gross profit	10	16	25	38	39
Research and development	21	30	18	15	14
Selling and marketing	13	17	26	29	34
General and administrative	12	24	18	21	21
Operating income	−36	−54	−36	−27	−31
Interest expense	0	0	3	6	6
Income before tax	−47	−59	−30	−39	−28
Income tax	0	0	0	0	0
Net income	−47	−59	−30	−39	−28
Diluted EPS	−$161.55	−$6.77	−$1.31	−$1.84	−$0.56
Diluted shares (average)	—	9m	25m	38m	50m
EBITDA	−36	−54	−35	−26	−30

US$ millions unless shown otherwise. Fiscal quarters.

Trisalus Life Sciences, Inc.: income statement, quarterly
Quarter	2024 Q3Sept 2024	2024 Q4Dec 2024	2025 Q1Mar 2025	2025 Q2Jun 2025	2025 Q3Sept 2025	2025 Q4Dec 2025	2026 Q1Mar 2026	2026 Q2Jun 2026
Revenue	7	8	9	11	12	13	9	11
Cost of revenue	1	1	1	2	2	2	1	2
Gross profit	6	7	8	9	10	11	8	10
Research and development	4	3	3	4	5	3	3	3
Selling and marketing	6	7	7	7	7	8	7	11
General and administrative	5	5	5	6	7	4	5	5
Operating income	−9	−8	−7	−7	−9	−3	−8	−10
Interest expense	1	1	1	1	1	1	1	1
Income before tax	−2	−10	−10	−8	−11	−10	2	−9
Income tax	−0	−0	0	−0	0	0	0	0
Net income	−2	−10	−10	−8	−11	−10	2	−9
Diluted EPS	−$0.12	−$0.40	−$0.39	−$0.27	−$0.96	−$0.12	$0.03	−$0.16
EBITDA	−9	−7	−7	−7	−9	−3	−8	−10

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: KRMD vs TLSI CLPT vs TLSI SNWV vs TLSI MYO vs TLSI

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Trisalus Life Sciences, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Trisalus Life Sciences, Inc.